Gilead Sciences presented data in a conference supporting the development of three investigational agents for the treatment of nonalcoholic steatohepatitis and primary sclerosing cholangitis, according to Street Insider.
Here are five takeaways:
1. The data was presented in oral and poster sessions at The International Liver Congress 2016 in Barcelona, Spain.
2. The first agent, simtuzumab, is a monoclonal antibody that is selective for LOXL2, an extracellular matrix enzyme that promotes fibrosis via the cross-linkage of collagen fibers.
3. The second agent, GS-4997, is a small-molecule inhibitor of apoptosis signal-regulating kinase 1, which promotes inflammation, apoptosis and fibrosis in settings of increased oxidative stress associated with NASH pathogenesis.
4. The third agent, GS-9674, is a selective non-steroidal agonist of the Farnesoid X receptor, a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver.
5. Gilead Sciences is a Foster City, Calif.-based biopharmaceutical company that discovers, develops and commercializes therapeutics.